Leukemia - Table of Contents alert Volume 28 Issue 5

If you are unable to see the message below, click here to view.

Advertisement BD FACSCanto™ has 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences. bdbiosciences.com/go/canto TABLE OF CONTENTS Volume 28, Issue 5 (May 2014) In this issue Reviews Original Articles Letters to the Editor Obituary Corrigendum Also new AOP Advertisement   Special pricing on Acute Myeloid Leukemia PDX Models   We are now engrafting NSG mice with patient-derived AML to make them readily available for you. Four AML models are available in the highly immunodeficient NSG mouse strain, which engrafts leukemia cells more effectively than other strains. Under the starter pricing plan you can receive 5 or more mice that have been confirmed for stable engraftment of patient-derived AML.  Learn about special pricing available for a limited time Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement Partnerships that drive high impact open science  Nature Partner Journals is a new series of online open access journals published in collaboration with world-renowned international partners. Each partnership in the portfolio brings together strong editorial leadership with world-class publication systems to deliver high-quality, peer-reviewed original research.   Reviews Top International Myeloma Working Group recommendations for global myeloma care H Ludwig, J S Miguel, M A Dimopoulos, A Palumbo, R Garcia Sanz, R Powles, S Lentzsch, W Ming Chen, J Hou, A Jurczyszyn, K Romeril, R Hajek, E Terpos, K Shimizu, D Joshua, V Hungria, A Rodriguez Morales, D Ben-Yehuda, P Sondergeld, E Zamagni and B Durie Leukemia 2014 28: 981-992; advance online publication, October 9, 2013; 10.1038/leu.2013.293 Abstract | Full Text Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma D Atanackovic, T Luetkens and N Kröger Leukemia 2014 28: 993-1000; advance online publication, October 23, 2013; 10.1038/leu.2013.310 Abstract | Full Text Original Articles Top ACUTE LEUKEMIAS Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG M Fiegl, M Unterhalt, W Kern, J Braess, K Spiekermann, P Staib, A Grüneisen, B Wörmann, D Schöndube, H Serve, A Reichle, M Hentrich, X Schiel, C Sauerland, A Heinecke, C Rieger, D Beelen, W E Berdel, T Büchner and W Hiddemann for the German AML Cooperative Group (AMLCG) Leukemia 2014 28: 1001-1007; advance online publication, October 22, 2013; 10.1038/leu.2013.297 Abstract | Full Text Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells F Akbari Moqadam, J M Boer, E A M Lange-Turenhout, R Pieters and M L den Boer Leukemia 2014 28: 1008-1014; advance online publication, October 23, 2013; 10.1038/leu.2013.308 Abstract | Full Text An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome C J Harrison, A V Moorman, C Schwab, A J Carroll, E A Raetz, M Devidas, S Strehl, K Nebral, J Harbott, A Teigler-Schlegel, M Zimmerman, N Dastuge, A Baruchel, J Soulier, M-F Auclerc, A Attarbaschi, G Mann, B Stark, G Cazzaniga, L Chilton, P Vandenberghe, E Forestier, I Haltrich, S C Raimondi, M Parihar, J-P Bourquin, J Tchinda, C Haferlach, A Vora, S P Hunger, N A Heerema and O A Haas on behalf of the Ponte di Legno International Workshop in Childhood Acute Lymphoblastic Leukemia Leukemia 2014 28: 1015-1021; advance online publication, October 29, 2013; 10.1038/leu.2013.317 Abstract | Full Text miR-9 is a tumor suppressor in pediatric AML with t(8;21) S Emmrich, J E Katsman-Kuipers, K Henke, M E Khatib, R Jammal, F Engeland, F Dasci, C M Zwaan, M L den Boer, L Verboon, J Stary, A Baruchel, V de Haas, A A Danen-van Oorschot, M Fornerod, R Pieters, D Reinhardt, J H Klusmann and M M van den Heuvel-Eibrink Leukemia 2014 28: 1022-1032; advance online publication, November 25, 2013; 10.1038/leu.2013.357 Abstract | Full Text MYELODYSPLASIAS Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS OPEN A F List, J M Bennett, M A Sekeres, B Skikne, T Fu, J M Shammo, S D Nimer, R D Knight and A Giagounidis on behalf of the MDS-003 Study Investigators Leukemia 2014 28: 1033-1040; advance online publication, October 22, 2013; 10.1038/leu.2013.305 Abstract | Full Text Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition H M Mehta, M Futami, T Glaubach, D W Lee, J R Andolina, Q Yang, Z Whichard, M Quinn, H F Lu, W M Kao, B Przychodzen, C A Sarkar, A Minella, J P Maciejewski and S J Corey Leukemia 2014 28: 1041-1051; advance online publication, October 30, 2013; 10.1038/leu.2013.321 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms OPEN E Tenedini, I Bernardis, V Artusi, L Artuso, E Roncaglia, P Guglielmelli, L Pieri, C Bogani, F Biamonte, G Rotunno, C Mannarelli, E Bianchi, A Pancrazzi, T Fanelli, G Malagoli Tagliazucchi, S Ferrari, R Manfredini, A M Vannucchi and E Tagliafico on behalf of AGIMM investigators Leukemia 2014 28: 1052-1059; advance online publication, October 22, 2013; 10.1038/leu.2013.302 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia F Arruga, B Gizdic, S Serra, T Vaisitti, C Ciardullo, M Coscia, L Laurenti, G D'Arena, O Jaksic, G Inghirami, D Rossi, G Gaidano and S Deaglio Leukemia 2014 28: 1060-1070; advance online publication, October 30, 2013; 10.1038/leu.2013.319 Abstract | Full Text STEM CELLS Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells OPEN Y Liu, H Cheng, S Gao, X Lu, F He, L Hu, D Hou, Z Zou, Y Li, H Zhang, J Xu, L Kang, Q Wang, W Yuan, S Gao and T Cheng Leukemia 2014 28: 1071-1080; advance online publication, October 22, 2013; 10.1038/leu.2013.304 Abstract | Full Text Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells X Huang, G J Spencer, J T Lynch, F Ciceri, T D D Somerville and T C P Somervaille Leukemia 2014 28: 1081-1091; advance online publication, October 29, 2013; 10.1038/leu.2013.316 Abstract | Full Text LYMPHOMA A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma OPEN E Horvilleur, T Sbarrato, K Hill, R V Spriggs, M Screen, P J Goodrem, K Sawicka, L C Chaplin, C Touriol, G Packham, K N Potter, S Dirnhofer, A Tzankov, M J S Dyer, M Bushell, M MacFarlane and A E Willis Leukemia 2014 28: 1092-1102; advance online publication, October 18, 2013; 10.1038/leu.2013.295 Abstract | Full Text Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma J Schmidt, I Salaverria, A Haake, I Bonzheim, P Adam, S Montes-Moreno, M A Piris, F Fend, R Siebert and L Quintanilla-Martinez Leukemia 2014 28: 1103-1112; advance online publication, October 23, 2013; 10.1038/leu.2013.307 Abstract | Full Text MYELOMA Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis M Gkotzamanidou, E Terpos, C Bamia, S A Kyrtopoulos, P P Sfikakis, M A Dimopoulos and V L Souliotis Leukemia 2014 28: 1113-1121; advance online publication, October 3, 2013; 10.1038/leu.2013.284 Abstract | Full Text Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients S K Kumar, A Dispenzieri, M Q Lacy, M A Gertz, F K Buadi, S Pandey, P Kapoor, D Dingli, S R Hayman, N Leung, J Lust, A McCurdy, S J Russell, S R Zeldenrust, R A Kyle and S V Rajkumar Leukemia 2014 28: 1122-1128; advance online publication, October 25, 2013; 10.1038/leu.2013.313 Abstract | Full Text Letters to the Editor Top Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy OPEN A Thakurta, A K Gandhi, M F Waldman, C Bjorklund, Y Ning, D Mendy, P Schafer, A Lopez-Girona, S Lentzsch, S A Schey, Y Calle, R Chelliah, R Z Orlowski, A Madan, H Avet-Loiseau and R Chopra Leukemia 2014 28: 1129-1131; advance online publication, October 29, 2013; 10.1038/leu.2013.315 Full Text What does MRD in leukemia really mean? J M Goldman and R P Gale Leukemia 2014 28: 1131; advance online publication, October 30, 2013; 10.1038/leu.2013.318 Full Text Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations E Manara, V Bisio, R Masetti, V Beqiri, R Rondelli, G Menna, C Micalizzi, N Santoro, F Locatelli, G Basso and M Pigazzi Leukemia 2014 28: 1132-1134; advance online publication, November 14, 2013; 10.1038/leu.2013.339 Full Text Cyclophosphamide as a first-line therapy in LGL leukemia OPEN A Moignet, Z Hasanali, R Zambello, L Pavan, B Bareau, O Tournilhac, M Roussel, T Fest, A Awwad, K Baab, G Semenzato, R Houot, T P Loughran, Jr and T Lamy Leukemia 2014 28: 1134-1136; advance online publication, November 27, 2013; 10.1038/leu.2013.359 Full Text Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A F Auer, F Rüschendorf, M Gombert, P Husemann, S Ginzel, S Izraeli, M Harit, M Weintraub, O Y Weinstein, I Lerer, P Stepensky, A Borkhardt and J Hauer Leukemia 2014 28: 1136-1138; advance online publication, November 29, 2013; 10.1038/leu.2013.363 Full Text Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis S L Peters, R A Hlady, J Opavska, D Klinkebiel, S J Pirruccello, G A Talmon, J G Sharp, L Wu, R Jaenisch, M A Simpson, A R Karpf and R Opavsky Leukemia 2014 28: 1138-1142; advance online publication, December 2, 2013; 10.1038/leu.2013.364 Full Text An MDS xenograft model utilizing a patient-derived cell line G W Rhyasen, M Wunderlich, K Tohyama, G Garcia-Manero, J C Mulloy and D T Starczynowski Leukemia 2014 28: 1142-1145; advance online publication, December 11, 2013; 10.1038/leu.2013.372 Full Text BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines N M Anderson, I Harrold, M R Mansour, T Sanda, M McKeown, N Nagykary, J E Bradner, G Lan Zhang, A T Look and H Feng Leukemia 2014 28: 1145-1148; advance online publication, December 17, 2013; 10.1038/leu.2013.377 Full Text Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia A Pellagatti, M Fernandez-Mercado, C Di Genua, M J Larrayoz, S Killick, H Dolatshad, A Burns, M J Calasanz, A Schuh and J Boultwood Leukemia 2014 28: 1148-1151; advance online publication, December 24, 2013; 10.1038/leu.2013.381 Full Text Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis OPEN J Chi, K A Nicolaou, V Nicolaidou, L Koumas, A Mitsidou, C Pierides, M Manoloukos, K Barbouti, F Melanthiou, C Prokopiou, G S Vassiliou and P Costeas Leukemia 2014 28: 1152-1154; advance online publication, December 24, 2013; 10.1038/leu.2013.382 Full Text ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma W Zhou, Y Yang, Z Gu, H Wang, J Xia, X Wu, X Zhan, D Levasseur, Y Zhou, S Janz, G Tricot, J Shi and F Zhan Leukemia 2014 28: 1155-1158; advance online publication, December 24, 2013; 10.1038/leu.2013.383 Full Text Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells Y Zhong, D El-Gamal, J A Dubovsky, K A Beckwith, B K Harrington, K E Williams, V M Goettl, S Jha, X Mo, J A Jones, J M Flynn, K J Maddocks, L A Andritsos, D McCauley, S Shacham, M Kauffman, J C Byrd and R Lapalombella Leukemia 2014 28: 1158-1163; advance online publication, January 13, 2014; 10.1038/leu.2014.9 Full Text B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies K Bojarczuk, M Siernicka, M Dwojak, M Bobrowicz, B Pyrzynska, P Gaj, M Karp, K Giannopoulos, D G Efremov, C Fauriat, J Golab and M Winiarska Leukemia 2014 28: 1163-1167; advance online publication, January 10, 2014; 10.1038/leu.2014.12 Full Text Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues OPEN M Goswami, N Hensel, B D Smith, G T Prince, L Qin, H I Levitsky, S A Strickland, M Jagasia, B N Savani, J W Fraser, H Sadrzadeh, T Rajkhowa, S Ito, N A Jain, M Battiwalla, A T Fathi, M J Levis, A J Barrett and C S Hourigan Leukemia 2014 28: 1167-1170; advance online publication, January 10, 2014; 10.1038/leu.2014.14 Full Text WTAP is a novel oncogenic protein in acute myeloid leukemia H Bansal, Q Yihua, S P Iyer, S Ganapathy, D Proia, L O Penalva, P J Uren, U Suresh, J S Carew, A B Karnad, S Weitman, G E Tomlinson, M K Rao, S M Kornblau and S Bansal Leukemia 2014 28: 1171-1174; advance online publication, January 13, 2014; 10.1038/leu.2014.16 Full Text Obituary Top Professor John M Goldman, 1938–2013: Gentleman and Scholar R P Gale Leukemia 2014 28: 1175-1176; advance online publication, March 21, 2014; 10.1038/leu.2014.36 Full Text Geoffrey Peter Herzig, MD Leukemia Pioneer (1941–2013) R P Gale and C D Bloomfield Leukemia 2014 28: 1177; advance online publication, March 21, 2014; 10.1038/leu.2014.43 Full Text Corrigendum Top A gene expression signature for high-risk multiple myeloma R Kuiper, A Broyl, Y de Knegt, M H van Vliet, E H van Beers, B van der Holt, L el Jarari, G Mulligan, W Gregory, G Morgan, H Goldschmidt, H M Lokhorst, M van Duin and P Sonneveld Leukemia 2014 28: 1178-1180; 10.1038/leu.2014.53 Full Text Advertisement BRAND NEW: Discounts on lab equipment Exclusive prices and information - all in one place! Check our listings before you buy.  VISIT MARKETPLACE TODAY    Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.